Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial.

J Ayurveda Integr Med · 2022 · PMC9595378 · PMID 36311474

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

3.3 Clinical assessment In the SOC + IP arm, there was a highly significant reduction in NRS from 4.3 ± 1.13 at day 0–1.74 ± 1.03 at day 4 (p < 0.0001) as shown in Table 3 .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.